Released Mar 12, 2013, after the close
10-K filed Mar 12, 2013, 71 days after period end · 0001193125-13-103307
Q4 2012 · 10-K
Revenue$1.44M$1.44M no prior Q4 2011 on file−33.7% vs Q3 2012
Net Income-$19.68M-$19.68M N/M vs Q4 2011N/M vs Q3 2012
EPS, diluted—
Gross Profit$1,229,000—
Operating Cash Flowderived-$5,178,000N/M
Margins · derived
Gross margin85.6%
Net margin-1370.3%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2012 | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|---|
| Revenue | $1.44M | — | — |
| Net Income | -$19.68M | $1.59M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR